FGF18介导成纤维细胞-白血病交互促进AML进展
本研究在AML骨髓微环境中发现成纤维细胞来源的FGF18上调,通过FGFR3-AKT-mTOR-IL-6轴形成正反馈环路,抑制CD8+ T细胞功能并促进白血病进展;阻断FGF18可恢复抗白血病免疫并与抗PD-1协同。
要点
- AML骨髓成纤维细胞FGF18上调,重组FGF18加速而敲除Fgf18延缓小鼠AML进展。
- FGF18经FGFR3激活AKT-mTOR并诱导IL-6,形成基质-白血病正反馈环路。
- FGF18中和抗体恢复CD8+ T细胞功能并与抗PD-1协同产生持久抗白血病免疫。
核心结论
- FGF18依赖的成纤维细胞-白血病交互轴驱动AML进展和免疫功能障碍,FGF18中和是潜在治疗策略。
研究设计与样本
- 研究采用AML骨髓微环境单细胞RNA测序、小鼠模型、CRISPR-Cas9筛选及FGF18中和抗体体内实验。
主要发现
- AML骨髓基质成纤维细胞Fgf18上调,重组FGF18加速AML进展,成纤维细胞特异性Fgf18缺失延缓疾病并改善小鼠生存。
- AML细胞中FGFR3信号介导富FGF18微环境中的白血病适应,Fgfr3缺失重现FGF18缺陷效应并限制体内白血病扩增。
- FGF18结合AML细胞FGFR3激活AKT-mTOR并诱导IL-6,IL-6自分泌强化白血病信号、旁分泌激活成纤维细胞JAK-STAT3,放大FGF18表达形成正反馈并抑制CD8+ T细胞功能。
- FGF18高表达与AML患者不良预后相关;FGF18中和抗体破坏反馈环路、恢复CD8+ T细胞功能并与抗PD-1协同。
临床怎么用
- FGF18表达水平或可作为AML预后评估的候选指标。
- FGF18中和抗体联合抗PD-1可能成为AML免疫治疗新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonhematopoietic stromal cells are essential regulators of hematopoiesis; however, their contribution to leukemogenesis and immune dysfunction remains poorly defined. In this study, we identified fibroblast-derived fibroblast growth factor 18 (FGF18) as a novel stromal cytokine that reprograms leukemia-immune interactions. Single-cell RNA sequencing of the bone marrow niche in acute myeloid leukemia (AML) revealed the upregulation of Fgf18 in stromal fibroblasts. Administration of recombinant FGF18 accelerated AML progression, whereas fibroblast-specific Fgf18 depletion markedly delayed disease development and improved the survival of mice. We performed a pooled CRISPR-Cas9 screen in AML cells and identified FGF receptor 3 (FGFR3) signaling as a critical mediator of leukemic fitness in the FGF18-rich microenvironment. Genetic loss of Fgfr3 in AML cells recapitulated the effects of FGF18 deficiency and limited leukemic expansion in vivo. Mechanistically, FGF18 binds to its receptor, FGFR3, on AML cells, activating the protein kinase B (AKT)-mechanistic target of rapamycin (mTOR) (AKT-mTOR) signaling pathway and inducing interleukin-6 (IL-6) production. IL-6 acts autocrinely to reinforce leukemic signaling and paracrinely to activate fibroblast JAK-STAT3 signaling, thereby amplifying stromal fibroblast FGF18 expression and forming a feed-forward loop that suppresses CD8+ T-cell effector function and weakens antileukemic immunity. Clinically, elevated FGF18 expression correlates with poor prognosis in patients with AML. To therapeutically target this malignant cross talk, we generated an FGF18-neutralizing antibody that disrupted the stromal-leukemia feedback loop, restored CD8+ T cell effector function, and synergized with anti-PD-1 therapy to elicit durable antileukemic immunity in vivo. Collectively, these findings identify an FGF18-dependent stromal-leukemia cross talk axis that drives AML progression and immune dysfunction, highlighting FGF18 neutralization as a potential therapeutic strategy.
引用
- Zhang W, Ye Z, Zhou X, et al. FGF18 mediates fibroblast-leukemia cross talk to promote acute myeloid leukemia progression. Blood. 2026. PMID: 42360909. doi:10.1182/blood.2026033125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。